Metropolis Healthcare (METROPOLIS | 542650): Filings Show a Margin Trajectory the Company Itself Has Quantified
Metropolis Healthcare's Q1FY27 results, filed with BSE on August 4, 2026, show consolidated revenue of ₹4,502.15 million (+16.6% YoY, +6.0% QoQ), with EBITDA margin expanding to 25.8% — up 110 bps YoY. PAT attributable to owners rose 25.8% YoY to ₹566.67 million. The company has since put a number on where it expects this to go.
Metropolis Healthcare's Q1FY27 results, filed with BSE on August 4, 2026, show consolidated revenue of ₹4,502.15 million (+16.6% YoY, +6.0% QoQ), with EBITDA margin expanding to 25.8% — up 110 bps YoY. PAT attributable to owners rose 25.8% YoY to ₹566.67 million. The company has since put a number on where it expects this to go.
This piece is compiled entirely from BSE filings made between July and September 2026. Nothing here is a recommendation.
The core disclosure: a quantified margin path
On August 27, 2026, Metropolis filed an investor presentation stating targets of "mid-teen revenue growth, 27–28% EBITDA margin over three years, and expansion to 1,000 own centres." Five days later, on September 2, 2026, a concall reiterated the 27–28% EBITDA margin target over the next 2–3 years, alongside 14–15% medium-term organic revenue growth guidance.
The Q4FY27 figure (27.4% EBITDA margin, as referenced in the Q1FY27 results filing) already sits close to that range. The Q1FY27 dip to 25.8% was described as a 160 bps sequential decline — the filings attribute the expansion trend to volume and mix improvement.
What the filings show, chronologically
July 5, 2026 — Business update (first in tracked history): Metropolis reported approximately 16% YoY consolidated revenue growth for Q1FY27, citing TruHealth Wellness and Specialty as the fastest-growing segments, with "B2C and B2B volume growth, and EBITDA margins improving YoY while remaining stable QoQ."
August 4, 2026 — Q1FY27 results: Revenue ₹450.22 crore, EBITDA ₹116.3 crore, PAT ₹56.67 crore. Revenue growth of 16.6% YoY was volume-led, with management attributing the operating margin improvement to mix. The filing notes this came "after two consecutive quarters of expansion."
August 10, 2026 — First concall in tracked history: Management reported broad-based 17% revenue growth and 210 bps margin expansion, maintaining FY27 guidance of 14–15% revenue growth and 100–150 bps margin improvement.
August 27, 2026 — Investor presentation (first in tracked history): The 27–28% EBITDA margin and 1,000-centre targets were filed. The same day, a separate filing disclosed the transfer of the External Quality Assessment Services (EQAS) Division to wholly owned subsidiary Metropolis Quality Solutions Private Limited via slump sale for INR 1.25 crore, discharged by issuing equity shares of the subsidiary.
September 2, 2026 — Concall: Management reiterated the 27–28% EBITDA margin ambition over 2–3 years, citing network utilization, specialty mix, and 100 planned basic radiology mini-hubs as drivers of the 14–15% medium-term organic revenue growth guidance.
The TruHealth mix target
A claim logged in the filings: Metropolis aims to increase TruHealth package revenue share from 18–20% to 25% by FY29. The filings describe higher-complexity testing (oncology, neurology, genomics) as providing "pricing uniformity across metro and tier-2/3 towns."
The Core Diagnostics turnaround, as stated
A separate claim in the filings: Metropolis targets bringing Core Diagnostics EBITDA margin "close to company-level EBITDA margins (20%-25%) by year 3 post-acquisition." The company's stated approach, per the filing's narrative: avoiding "high-multiple aggregator bidding wars" and focusing on "turning around break-even, high-skill specialty assets."
What the filings say comes next
These are stated targets, not projections:
- FY27 guidance: 14–15% revenue growth, 100–150 bps margin improvement (concall, August 10, 2026)
- Medium-term (2–3 years): 27–28% EBITDA margin, 14–15% organic revenue growth, 1,000 own centres (investor presentation, August 27, 2026; concall, September 2, 2026)
- TruHealth: 25% revenue share by FY29 (claim in filings)
- Core Diagnostics: 20–25% EBITDA margin by year 3 post-acquisition (claim in filings)
The filings describe a company that has quantified its margin trajectory, disclosed the drivers (volume, mix, network utilization), and set observable milestones. Whether those milestones are met is a matter for future filings — the next results release will show whether Q2FY27 margin tracks toward or away from the stated 27–28% range.
The filing evidence
| Date | What the filing said | Detail | Source |
|---|---|---|---|
| TruHealth revenue contribution — 25% — by FY29 | Metropolis Healthcare Limited aims to increase TruHealth package revenue share from 18%-20% to 25%. | ||
| 4 Aug 2026 | Metropolis Healthcare Q1FY27: Revenue ₹450 Cr (+16.6% YoY), PAT ₹56.7 Cr (+25.8% YoY), EBITDA margin expands to 25.8% (+110bps YoY) driven by volume and mix improvement; margin sequential dip of 160bps from Q4FY27's 27.4%. | filing | |
| 4 Aug 2026 | Q1FY27 consolidated revenue rose to ₹4,502.15 million (+16.6% YoY, +6.0% QoQ) while EBITDA margin expanded to 25.8%, extending the margin recovery and driving PAT attributable to owners up 25.8% YoY to ₹566.67 million. | filing | |
| 4 Aug 2026 | Q1FY27 revenue was ₹450.22 crore, up 16.6% YoY, while EBITDA was ₹116.3 crore and PAT ₹56.67 crore; volume-led growth and richer mix lifted operating margin after two consecutive quarters of expansion. | filing | |
| Core Diagnostics EBITDA margin turnaround — 20%-25% — by FY28 | Metropolis Healthcare Limited targets bringing Core Diagnostics EBITDA margin close to company-level EBITDA margins (20%-25%) by year 3 post-acquisition. | ||
| 10 Aug 2026 | Q1FY27 sees broad-based 17% revenue growth and 210 bps margin expansion; management maintains FY27 guidance of 14-15% revenue growth and 100-150 bps margin improvement, driven by volume and specialty mix. | filing | |
| 27 Aug 2026 | Metropolis Healthcare targets mid-teen revenue growth, 27–28% EBITDA margin over three years, and expansion to 1,000 own centres. | filing | |
| 5 Jul 2026 | Metropolis Healthcare reports ~16% YoY revenue growth in Q1FY27, driven by patient volumes and product mix improvement | Metropolis Healthcare issued a business update for Q1FY27 (quarter ended June 30, 2026), highlighting consolidated revenue growth of approximately 16% year-on-year, with TruHealth Wellness and Specialty segments as the fastest growing, B2C and B2B volume growth, and EBITDA margins improving YoY while remaining stable QoQ. | filing |
| 27 Aug 2026 | Metropolis Healthcare completes transfer of its External Quality Assessment Services Business Division to subsidiary Metropolis Quality Solutions Private Limited via slump sale for INR 1.25 crore. | The company transferred its EQAS Division to its wholly owned subsidiary, Metropolis Quality Solutions Private Limited, as a going concern on a slump sale basis for a consideration of INR 1.25 crore, discharged by issuance of equity shares of the subsidiary. The transfer is effective August 27, 2026. | filing |
| 2 Sept 2026 | Metropolis targets expanding EBITDA margins to 27%-28% over the next 2-3 years while guiding for 14%-15% medium-term organic revenue growth driven by network utilization, specialty mix, and 100 planned basic radiology mini-hubs. | filing |
Quick answers
- What did Metropolis Healthcare disclose?
- Metropolis Healthcare's Q1FY27 results, filed with BSE on August 4, 2026, show consolidated revenue of ₹4,502.15 million (+16.6% YoY, +6.0% QoQ), with EBITDA margin expanding to 25.8% — up 110 bps YoY. PAT attributable to owners rose 25.8% YoY to ₹566.67 million. The company has since put a number on where it expects this to go.
- What are the key numbers?
- On August 27, 2026, Metropolis filed an investor presentation stating targets of "mid-teen revenue growth, 27–28% EBITDA margin over three years, and expansion to 1,000 own centres."
- What does Metropolis Healthcare say comes next?
- These are stated targets, not projections:
Research and educational content only. Not investment advice. Drafted from regulatory filings and published automatically — see our editorial policy.